• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Hinge Health (HNGE) Reports Q2 Results, Is The Stock Already Fully Valued?

    Simply Wall St·08/17/2026 18:25:57
    語音播報

    Hinge Health (HNGE) drew fresh attention on 4 August 2026 after reporting second quarter 2026 results, issuing updated revenue guidance for the year, and completing a sizeable share repurchase program.

    See our latest analysis for Hinge Health.

    Against this backdrop, Hinge Health’s share price has climbed to $88.49, with a 90 day share price return of 61.01% and a year to date share price return of 94.23%. The 1 year total shareholder return of 49.91% indicates that recent momentum remains relatively concentrated in the shorter term.

    If Hinge Health’s recent jump has you rethinking your exposure to digital health and automation, it may be a good time to scan for other healthcare AI opportunities using the 41 healthcare AI stocks

    After a sharp move in Hinge Health following its latest results, the real fork in the road is clear. Do you lean into the current price, or wait and hope valuation offers a cleaner entry later?

    Most Popular Narrative: 2.6% Undervalued

    Hinge Health’s most followed valuation narrative points to a fair value of $90.87, sitting slightly above the latest close at $88.49 and framing today’s move as only a modest discount.

    Several research notes highlight new products such as HingeSelect, surgical support, and the Migraine program as potential incremental revenue drivers that support multiyear growth frameworks.

    Read the complete narrative. Read the complete narrative.

    Want to see what sits behind that fair value gap? The story leans heavily on faster revenue gains, a sharp margin shift, and a future earnings profile that looks very different from today.

    Result: Fair Value of $90.87 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Hinge Health’s story can change quickly if employers pull back on digital MSK benefits or if tighter regulation slows the rollout of its AI tools.

    Find out about the key risks to this Hinge Health narrative.

    Another View on Hinge Health’s Valuation

    The first narrative casts Hinge Health as modestly undervalued against a $90.87 fair value. The preferred earnings based yardstick paints a sharper picture. HNGE trades on a P/E of 66.6x versus a fair ratio of 37.9x, the US Healthcare industry at 25.3x, and peers at 66.4x. That gap suggests investors are already paying upfront for a lot of future growth, so it may be useful to consider how comfortable you are with that valuation risk if sentiment cools.

    To see how this earnings based view compares with other approaches, including cash flow focused work, take a closer look at our detailed valuation breakdown via the See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:HNGE P/E Ratio as at Aug 2026
    NYSE:HNGE P/E Ratio as at Aug 2026

    Next Steps

    Feeling that the Hinge Health story is leaning optimistic right now? Take a closer look at what the market is rewarding and check the 4 key rewards

    Looking for more investment ideas beyond Hinge Health?

    If Hinge Health has sharpened your focus, take the chance to broaden your watchlist with other stocks that match your risk, income, and quality preferences.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.